CAMP4 Therapeutics Corporation (CAMP)
CAMP moved a median of 0.00% 30 minutes after news, and -2.67% by the close. How CAMP actually reacts to news — the realized, point-in-time move the market made, measured across 81 labeled events over the last three years with zero look-ahead.
CAMP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 80 |
| 30-min | 0.00% | 48% | 80 |
| 60-min | -0.48% | 43% | 80 |
| to close | -2.67% | 32% | 81 |
| Middle 50% of CAMP reactions | -2.46% to +2.81% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 81 |
Half of all CAMP4 Therapeutics Corporation news events land between -2.46% and +2.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CAMP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CAMP's baseline. Nothing else.
Recent CAMP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference | Press release | GlobeNewswire | -0.30% | +3.00% | |
| CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder | Press release | GlobeNewswire | +0.47% | +0.93% | |
| CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 | Press release | GlobeNewswire | +0.34% | -2.70% | |
| CAMP4 to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.82% | -1.30% | |
| CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -5.56% | +20.89% | |
| CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement | Press release | GlobeNewswire | -0.91% | -2.80% | |
| CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder | Press release | GlobeNewswire | +3.96% | +4.27% | |
| CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.77% | -14.43% | |
| CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.44% | +0.48% | |
| CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +0.67% | |
| CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder | Press release | GlobeNewswire | +5.11% | -2.67% | |
| CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -3.08% | +5.69% | |
| CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation | Press release | GlobeNewswire | +1.38% | -1.61% | |
| CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.75% | +0.22% | |
| CAMP4 Appoints Michael MacLean to its Board of Directors | Press release | GlobeNewswire | -0.03% | -1.31% | |
| CAMP4 to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +4.06% | +49.76% | |
| CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -0.22% | -6.04% | |
| CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +9.65% | +3.91% | |
| CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -5.08% | -19.42% | |
| CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.71% | -0.33% | |
| CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries | Press release | GlobeNewswire | +2.20% | +1.14% | |
| CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock | Press release | GlobeNewswire | +2.20% | +1.14% | |
| CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.98% | +7.14% | |
| CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.16% | -4.32% | |
| CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -2.07% | -2.30% | |
| CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 | Press release | GlobeNewswire | -0.33% | -1.67% | |
| CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders | Press release | GlobeNewswire | -2.09% | -9.12% | |
| CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -2.15% | +7.74% | |
| CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Socie | Press release | GlobeNewswire | -2.36% | +8.49% | |
| CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -8.10% | -11.43% | |
| CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting | Press release | GlobeNewswire | +0.00% | -5.41% | |
| CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | -14.03% | |
| CAMP4 Appoints Multiple Industry Veterans to its Board of Directors | Press release | GlobeNewswire | +0.00% | +0.73% | |
| CAMP4 to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -4.21% | -7.66% | |
| CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.00% | -8.14% | |
| CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones | Press release | GlobeNewswire | +0.00% | -0.45% | |
| CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors | Press release | GlobeNewswire | +0.00% | -6.64% | |
| CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference | Press release | GlobeNewswire | +0.83% | +5.63% | |
| CAMP4 Reports Third Quarter 2024 Financial Results | Press release | GlobeNewswire | +15.69% | -3.56% | |
| CAMP4 Announces Pricing of Initial Public Offering | Press release | GlobeNewswire | +0.36% | -3.94% | |
| CalAmp Reaches Comprehensive Agreement to Significantly Reduce Debt, Go Private, and Strengthen Financial Flexibility to Support Innovation Through a Consensual Financial Restructuring | Press release | GlobeNewswire | -10.71% | -27.86% | |
| Form 8-K CalAmp Corp. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | -18.28% | |
| Form 8-K CalAmp Corp. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -10.71% | -27.86% | |
| Form NT 10-K CalAmp Corp. For: Feb 29 | SEC filing · Form NT | SEC EDGAR | +0.00% | -19.34% | |
| CalAmp Enhances School Bus Solutions Suite with Dispatch Monitor | Press release | GlobeNewswire | — | +3.93% | |
| Form 8-K CalAmp Corp. For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.59% | |
| 12th Annual CompassIntel Award Winners Announced in IoT, Mobile/Business Tech, and Emerging Tech | Press release | PR Web | -0.32% | +0.00% | |
| CalAmp Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.31% | -4.66% | |
| Form 8-K CalAmp Corp. For: Feb 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.81% | |
| Form 8-K CalAmp Corp. For: Jan 25 | SEC filing · Form 8-K | SEC EDGAR | -0.98% | -4.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CAMP section they belong to.
Where else CAMP is measured.
CAMP earnings → · Analyst actions → · SEC filings →
Other Technology names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ARCELIK A S UNSP/ADR (ACKAY) | 81 | 0.00% | 4% |
| Diagnos Inc (ADK_CDNX) | 81 | 0.00% | 27% |
| SQUARE ENIX HLDGS U/ADR (SQNNY) | 81 | 0.00% | 19% |
| Shopify Inc (SHOP_TSE) | 79 | -0.45% | 0% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Technology names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CAMP4 Therapeutics Corporation's median reaction calculated?
Every labeled CAMP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 81 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of CAMP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CAMP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.